What's in Canadian Heart Research Centre's pipeline?

Canadian Heart Research Centre has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Canadian Heart Research Centre's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/canadian-heart-research-centre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Canadian Heart Research Centre — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Canadian Heart Research Centre pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Avandia and Amaryl	Avandia and Amaryl	phase 3	Thiazolidinedione + Sulfonylurea combination	PPAR-γ (rosiglitazone); Sulfonylurea receptor / ATP-sensitive potassium channel (glimepiride)	Diabetes

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Canadian Heart Research Centre:

Cite this brief

Drug Landscape (2026). Canadian Heart Research Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/canadian-heart-research-centre. Accessed 2026-05-17.